SCHEMBL5652989

SCHEMBL5652989

Nc1ccc(N2CCOC2=O)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
GFER P55789 2/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
PARP1 P09874 1/20 0.40
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
IDH1 O75874 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PDE10A Q9Y233 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8305764 0.83 LMNA (0.41) ALDH1A1LMNAPARP1SMN1; SMN2IDH1
SCHEMBL5388815 0.81 MAPT (0.50) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL11486385 0.81 MAPT (0.57) MAPTALDH1A1TDP1GAASMN1; SMN2
SCHEMBL19308380 0.78 ATAD2 (0.39) MAPTALDH1A1GFERMAPK1PARP1
SCHEMBL77406 0.78 MAPT (0.43) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL2750210 0.78 MEN1 (0.56) MAPTALDH1A1LMNAPARP1SMN1; SMN2
SCHEMBL5654099 0.78 ALDH1A1 (0.57) MAPTALDH1A1LMNATDP1GAA
SCHEMBL4014556 0.77 ALDH1A1 (0.46) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL77700 0.77 ALDH1A1 (0.46) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL1845432 0.77 PARP1 (0.42) PARP1GAAIDH1PDE10ACMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ MAPT 1440/4885ALDH1A1 2948/4885GFER 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.